Evidence map›Paper›PMID 35036404›Full record

ArticleFrontiers in cell and developmental biology2021

HDAC Inhibitor Titration of Transcription and Axolotl Tail Regeneration.

S Randal Voss, Jeramiah J Smith, Raissa F Cecil, Mirindi Kabangu, Timothy J Duerr, James R Monaghan, Nataliya Timoshevskaya, Larissa V Ponomareva, Jon S Thorson, Alan Veliz-Cuba and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

S Randal VossDepartment of Neuroscience, Spinal Cord and Brain Injury Research Center, and Ambystoma Genetic Stock Center, University of Kentucky, Lexington, KY, United States.
Jeramiah J SmithDepartment of Biology, University of Kentucky, Lexington, KY, United States.
Raissa F CecilDepartment of Neuroscience, Spinal Cord and Brain Injury Research Center, and Ambystoma Genetic Stock Center, University of Kentucky, Lexington, KY, United States.
Mirindi KabanguDepartment of Neuroscience, Spinal Cord and Brain Injury Research Center, and Ambystoma Genetic Stock Center, University of Kentucky, Lexington, KY, United States.
Timothy J DuerrDepartment of Biology and Institute for Chemical Imaging of Living Systems, Northeastern University, Boston, MA, United States.
James R MonaghanDepartment of Biology and Institute for Chemical Imaging of Living Systems, Northeastern University, Boston, MA, United States.
Nataliya TimoshevskayaDepartment of Biology, University of Kentucky, Lexington, KY, United States.
Larissa V PonomarevaCollege of Pharmacy and Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, United States.
Jon S ThorsonCollege of Pharmacy and Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, United States.
Alan Veliz-CubaDepartment of Mathematics, University of Dayton, Dayton, OH, United States.
David MurrugarraDepartment of Mathematics, University of Kentucky, Lexington, KY, United States.
University of Kentucky · USNortheastern University · USUniversity of Dayton · US

Funding

Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI M. Ashfaqul Alam · 2020 to 2026
$18.7M
Ambystoma Genetic Stock Center - Revision to Include Curation and Informatics ComponentP40OD019794 · OD · UNIVERSITY OF KENTUCKY · PI Stephen Randal Voss · 2015 to 2026
$6.3M
Research Resources for Model AmphibiansR24OD010435 · OD · UNIVERSITY OF KENTUCKY · PI SMITH, JERAMIAH JAMES, VOSS, STEPHEN RANDAL · 2012 to 2025
$5.7M
Developing Regeneration Resources for a Model AmphibianR24OD021479 · OD · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT, VOSS, STEPHEN RANDAL · 2016 to 2019
$2.3M
Mechanisms of skeletal patterning during limb development and regenerationR01HD099174 · NICHD · NORTHEASTERN UNIVERSITY · PI MONAGHAN, JAMES R · 2020 to 2024
$1.6M
NICHD NIH HHS R01 HD099174NIGMS NIH HHS P20 GM130456NIH HHS P40 OD019794NIH HHS R24 OD010435NIH HHS R24 OD021479
6 · The paper itself

Abstract

New patterns of gene expression are enacted and regulated during tissue regeneration. Histone deacetylases (HDACs) regulate gene expression by removing acetylated lysine residues from histones and proteins that function directly or indirectly in transcriptional regulation. Previously we showed that romidepsin, an FDA-approved HDAC inhibitor, potently blocks axolotl embryo tail regeneration by altering initial transcriptional responses to injury. Here, we report on the concentration-dependent effect of romidepsin on transcription and regeneration outcome, introducing an experimental and conceptual framework for investigating small molecule mechanisms of action. A range of romidepsin concentrations (0-10 μM) were administered from 0 to 6 or 0 to 12 h post amputation (HPA) and distal tail tip tissue was collected for gene expression analysis. Above a threshold concentration, romidepsin potently inhibited regeneration. Sigmoidal and biphasic transcription response curve modeling identified genes with inflection points aligning to the threshold concentration defining regenerative failure verses success. Regeneration inhibitory concentrations of romidepsin increased and decreased the expression of key genes. Genes that associate with oxidative stress, negative regulation of cell signaling, negative regulation of cell cycle progression, and cellular differentiation were increased, while genes that are typically up-regulated during appendage regeneration were decreased, including genes expressed by fibroblast-like progenitor cells. Using single-nuclei RNA-Seq at 6 HPA, we found that key genes were altered by romidepin in the same direction across multiple cell types. Our results implicate HDAC activity as a transcriptional mechanism that operates across cell types to regulate the alternative expression of genes that associate with regenerative success versus failure outcomes.

Indexed as

axolotl (Ambystoma mexicanum)CRISPR-Cas9HDACregenerationromidepsinsingle nuclei RNA-seqtranscription

Identifiers

PMID35036404
PMCPMC8759488
OpenAlexW4205237485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.